TNF dose reduction in isolated limb perfusion
- 30 November 2005
- journal article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 31 (9) , 1011-1019
- https://doi.org/10.1016/j.ejso.2005.07.003
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Hyperthermic Isolated Limb Perfusion With Low-Dose Tumor Necrosis Factor-α and Melphalan for Bulky In-Transit Melanoma MetastasesAnnals of Surgical Oncology, 2004
- Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusionBritish Journal of Cancer, 2000
- Soft tissue limb sarcomasCancer, 1999
- Hyperthermic Antiblastic Perfusion with Alpha Tumor Necrosis Factor and Doxorubicin for the Treatment of Soft Tissue Limb Sarcoma in Candidates for AmputationJournal of Immunotherapy, 1999
- Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in ratsBritish Journal of Cancer, 1999
- Isolated Limb Perfusion with Tumor Necrosis Factor and Melphalan for Limb Salvage in 186 Patients with Locally Advanced Soft Tissue Extremity SarcomasAnnals of Surgery, 1996
- Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.Journal of Clinical Oncology, 1996
- Low-dose tumour necrosis factor α and melphalan in hyperthermic isolated limb perfusionBritish Journal of Surgery, 1993
- High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.Journal of Clinical Oncology, 1992
- Chemotherapy of CancerAnnals of Surgery, 1958